[{"id":"2e65ab02-5455-476f-a9fc-8810d776844a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01386385","created_at":"2021-01-19T08:29:02.253Z","updated_at":"2025-02-25T16:36:10.447Z","phase":"Phase 1/2","brief_title":"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01386385","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ERCC1 • XRCC1","pipe":" | ","alterations":" ERCC1 expression","tags":["ERCC1 • XRCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERCC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • veliparib (ABT-888)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 06/20/2011","start_date":" 06/20/2011","primary_txt":" Primary completion: 05/26/2019","primary_completion_date":" 05/26/2019","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"49fd164b-4fd1-4bd8-932f-08c45dda5bd8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02128906","created_at":"2021-01-18T09:52:10.167Z","updated_at":"2024-07-02T16:35:15.614Z","phase":"Phase 2","brief_title":"Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design","source_id_and_acronym":"NCT02128906","lead_sponsor":"Christopher Wilke","biomarkers":" ERCC1","pipe":" | ","alterations":" ERCC1 expression","tags":["ERCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERCC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • docetaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/23/2013","start_date":" 12/23/2013","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-03-08"},{"id":"197da2b8-464a-430c-a915-acaaae8ac86a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05832593","created_at":"2023-04-27T14:04:59.039Z","updated_at":"2024-07-02T16:35:49.443Z","phase":"","brief_title":"Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy.","source_id_and_acronym":"NCT05832593","lead_sponsor":"Assiut University","biomarkers":" ERCC1","pipe":" | ","alterations":" ERCC1 expression","tags":["ERCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERCC1 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-04-27"},{"id":"4b22131b-479c-418d-9460-87ca3133481d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00792701","created_at":"2021-01-18T03:00:30.679Z","updated_at":"2024-07-02T16:36:49.078Z","phase":"Phase 2","brief_title":"S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT00792701","lead_sponsor":"Southwest Oncology Group","biomarkers":" ERCC1 • RRM1","pipe":" | ","alterations":" ERCC1 expression • RRM1 expression","tags":["ERCC1 • RRM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERCC1 expression • RRM1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine"],"overall_status":"Completed","enrollment":" Enrollment 85","initiation":"Initiation: 11/01/2008","start_date":" 11/01/2008","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2020-03-06"},{"id":"282ad5ed-28a5-4fcf-8a9b-672046063b64","acronym":"","url":"https://clinicaltrials.gov/study/NCT01059552","created_at":"2021-01-18T04:10:21.319Z","updated_at":"2024-07-02T16:36:53.163Z","phase":"Phase 1","brief_title":"Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT01059552","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" ERCC1 • HDAC1","pipe":" | ","alterations":" ERCC1 expression","tags":["ERCC1 • HDAC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERCC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Zolinza (vorinostat)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 12/16/2009","start_date":" 12/16/2009","primary_txt":" Primary completion: 07/22/2015","primary_completion_date":" 07/22/2015","study_txt":" Completion: 10/21/2019","study_completion_date":" 10/21/2019","last_update_posted":"2019-11-27"},{"id":"665a24f0-30ae-47ae-bd4a-55761e74693b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02948075","created_at":"2021-01-18T14:28:35.503Z","updated_at":"2024-07-02T16:37:09.434Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy","source_id_and_acronym":"NCT02948075","lead_sponsor":"NewVac LLC","biomarkers":" BRCA1 • ERCC1 • CDH1","pipe":" | ","alterations":" BRCA1 expression • CDH1 expression • ERCC1 expression","tags":["BRCA1 • ERCC1 • CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 expression • CDH1 expression • ERCC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • quisinostat (JNJ 26481585)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 06/16/2017","study_completion_date":" 06/16/2017","last_update_posted":"2018-06-27"},{"id":"bad79930-3a02-4ffd-8c32-3e569beebcf1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01192750","created_at":"2021-01-18T04:46:22.150Z","updated_at":"2024-07-02T16:37:22.148Z","phase":"","brief_title":"Biomakers in Tissue Samples From Patients With Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Previously Treated With Cisplatin With or Without Cetuximab","source_id_and_acronym":"NCT01192750","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" ERCC1","pipe":" | ","alterations":" ERCC1 expression","tags":["ERCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERCC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin"],"overall_status":"Completed","enrollment":" Enrollment 79","initiation":"Initiation: 08/05/2010","start_date":" 08/05/2010","primary_txt":" Primary completion: 10/05/2010","primary_completion_date":" 10/05/2010","study_txt":" Completion: 10/05/2010","study_completion_date":" 10/05/2010","last_update_posted":"2017-05-17"},{"id":"270f6c2c-c1ee-4f28-b87f-f30b7453ad9c","acronym":"MADe IT","url":"https://clinicaltrials.gov/study/NCT00215930","created_at":"2021-01-18T00:43:55.513Z","updated_at":"2024-07-02T16:37:24.162Z","phase":"Phase 2","brief_title":"The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT00215930 - MADe IT","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ERCC1 • RRM1","pipe":" | ","alterations":" ERCC1 expression • RRM1 expression","tags":["ERCC1 • RRM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERCC1 expression • RRM1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • docetaxel • vinorelbine tartrate"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 02/01/2004","start_date":" 02/01/2004","primary_txt":" Primary completion: 10/01/2009","primary_completion_date":" 10/01/2009","study_txt":" Completion: 10/01/2009","study_completion_date":" 10/01/2009","last_update_posted":"2017-03-23"}]